80 °C oil bath until the starting material had been completely
consumed as detected by TLC. The solution was then allowed to
cool to room temperature, and the DMF was evaporated in
vacuum to leave a yellowish oil. The crude oil was then diluted
with DCM (150 mL), washed with saturated NaCl solution (3 ×
30 mL), and dried with MgSO4. After removal of the solvent,
the mixture was purified by column chromatography (hexanes–
EtOAc, 6 : 1) and then recrystallized (CH2Cl2–hexanes) to give
40 °C oil bath until the starting material had been completely
consumed as detected by TLC. The solution was then allowed to
cool to room temperature, and the DMF was evaporated under
vacuum to leave a yellowish oil. The crude oil was then diluted
with DCM (150 mL), washed with saturated NaCl solution (3 ×
30 mL), and dried with MgSO4. After removal of the solvent,
the mixture was purified by column chromatography (hexanes–
EtOAc, 5 : 1) and then recrystallized (CH2Cl2–hexanes) to give
3b (66.4 mg, 0.19 mmol, 19%) as
a
colorless solid.
8b (150 mg, 0.42 mmol, 28%) as a colorless solid.
1
1
Mp. 152–153 °C. H NMR (400 MHz, CDCl3): δ 1.13 (s, 6 H),
2.40 (s, 2 H), 2.66 (s, 3 H), 2.73 (s, 2 H), 7.60 (dd, J = 8.70,
2.50 Hz, 1 H), 7.83 (dd, J = 5.60, 3.00, 2 H). 13C-Apt
(100 MHz, CDCl3): δ 12.27, 28.44 (2C), 34.99, 36.87, 53.34,
116.04, 116.84, 117.01, 124.70, 129.64, 134.12, 138.26, 141.77,
156.94, 194.81. HRMS (ESI) calcd for C17H17N3OBr: 358.0555
[M + H]+; Found 358.0549.
Mp. 159–160 °C. H NMR (400 MHz, CDCl3): δ 1.13 (s, 6 H),
2.40 (s, 2 H), 2.70 (s, 3 H), 2.73 (s, 2 H), 7.57 (dd, J = 8.40,
2.00 Hz, 1 H), 7.78 (d, J = 8.40, 1 H), 7.93 (d, J = 1.90, 1 H).
13C-Apt (100 MHz, CDCl3): δ 12.50, 28.41 (2C), 34.91, 36.68,
53.36, 114.99, 116.40, 117.15, 123.07, 126.06, 128.85, 134.77,
142.07, 142.67, 157.13, 194.73. HRMS (ESI) calcd for
C17H17N3OBr: 358.0555 [M + H]+; Found 358.0556.
2-({2-[Bis(pyridin-2-ylmethyl)amino]ethyl}amino)-5-(3,6,6-
trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-2-yl)benzamide
(CdABA′). A Schlenk flask was charged with compound 3b
(78.0 mg, 0.22 mmol, 1.00 equiv.), BPEA (63.4 mg, 0.26 mmol,
1.17 equiv.), sodium tert-butoxide (96 mg, 1.00 mmol, 4.50
equiv.), palladium chloride (10 mg, 0.06 mmol, 0.27 equiv.),
DPPF (48 mg, 0.086 mmol, 0.39 equiv.), and toluene (8 mL)
under argon. The flask was immersed in an oil bath at 100 °C
with stirring until the starting material had completely dis-
appeared as judged by TLC analysis. The solution was then
allowed to cool to room temperature, was diluted with DCM
(100 mL), filtered through Celite, and concentrated. The crude
product was then purified further by column chromatography
(CH2Cl2–MeOH, 40 : 1) on silica gel to give 6 (61.6 mg,
0.12 mmol, 54%) as a viscous oil. 1H NMR (400 MHz, CDCl3):
δ 1.12 (s, 6 H), 2.37 (s, 2 H), 2.52 (s, 3H), 2.70 (s, 2 H), 2.96 (t,
J = 5.60 Hz, 2 H), 3.28 (s, 2H), 3.94 (s, 4 H), 6.12 (bs, 1 H),
6.61 (d, J = 9.00 Hz, 2 H), 7.18 (dd, J = 6.70, 5.50 Hz, 2 H),
7.37 (dd, J = 9.00, 2.50 Hz, 1 H), 7.46 (d, J = 2.50 Hz, 1 H)
7.60 (d, J = 7.80 Hz, 2 H), 7.71 (td, J = 7.70, 1.60 Hz, 2 H),
8.57 (d, J = 4.70 Hz, 2 H). Then, by using the same procedure
as that described for the preparation of CdABA, compound 6
was hydrated with KOH catalyzed by H2O2 to give CdABA′ in
90% yield as a colorless solid. Mp. 235–236.5 °C. 1H NMR
(400 MHz, CDCl3): δ 1.12 (s, 6 H), 2.37 (s, 2 H), 2.50 (s, 3H),
2.70 (s, 2 H), 2.93 (t, J = 5.70 Hz, 2 H), 3.33 (t, J = 5.80 Hz,
2H), 3.94 (s, 4 H), 5.87 (bs, 2 H), 6.63 (d, J = 8.90 Hz, 1 H),
7.14–7.18 (m, 2 H), 7.24 (dd, J = 8.90, 2.40 Hz, 1 H), 7.48 (d,
J = 2.40 Hz, 1 H), 7.68 (t, J = 7.60 Hz, 2 H), 7.76 (d, J = 7.80 Hz,
2 H), 8.52 (d, J = 4.70 Hz, 2 H). 13C-Apt (100 MHz, CDCl3):
δ 11.97, 28.49 (2C), 29.67, 35.08, 40.32, 52.51, 53.29, 60.35
(2C), 111.80, 113.52, 115.51, 122.21 (2C), 123.41 (2C), 125.50,
125.83, 130.05, 136.78 (2C), 141.76, 148.78 (2C), 149.70,
155.73, 158.83 (2C), 170.90, 194.90. HRMS (ESI) calcd for
C31H36N7O2: 538.2930 [M + H]+; Found 538.2929.
2-({2-[Bis(pyridin-2-ylmethyl)amino]ethyl}amino)-4-(3,6,6-
trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-2-yl)benzamide
(ZnABA′). A Schlenk flask was charged with compound 8b
(115.5 mg, 0.33 mmol, 1.20 equiv.), BPEA (66.7 mg,
0.275 mmol, 1.00 equiv.), sodium tert-butoxide (96 mg,
1.00 mmol, 3.60 equiv.), palladium chloride (10 mg, 0.06 mmol,
0.22 equiv.), DPPF (48 mg, 0.086 mmol, 0.31 equiv.), and
toluene (8 mL) under argon. The flask was immersed in an oil
bath at 100 °C with stirring until the starting material had com-
pletely disappeared as judged by TLC analysis. The solution was
then allowed to cool to room temperature, was diluted with
DCM (100 mL), filtered through Celite, and concentrated. The
crude product was then purified further by column chromato-
graphy (CH2Cl2–MeOH, 40 : 1) on silica gel to give 9 (73.9 mg,
0.14 mmol, 53%) as a viscous oil. 1H NMR (400 MHz, CDCl3):
δ 1.12 (s, 6 H), 2.38 (s, 2 H), 2.60 (s, 3H), 2.71 (s, 2 H), 2.93 (t,
J = 5.60 Hz, 2 H), 3.27 (d, J = 3.70 Hz, 2H), 3.91 (s, 4 H), 6.09
(bs, 1 H), 6.66–6.68 (m, 2 H), 7.16 (dd, J = 6.70, 5.60 Hz, 2 H),
7.49 (d, J = 8.20 Hz, 1 H), 7.58 (d, J = 7.80 Hz, 2 H), 7.69 (td,
J = 7.70, 1.5 Hz, 2 H), 8.55 (d, J = 4.80 Hz, 2 H). Then, by
using the same procedure as that described for the preparation of
CdABA, compound 9 was hydrated with KOH catalyzed by
H2O2 to give ZnABA′ in 90% yield as a colorless solid.
1
Mp. 198–199 °C. H NMR (400 MHz, CDCl3): δ 1.13 (s, 6 H),
2.38 (s, 2 H), 2.57 (s, 3H), 2.72 (s, 2 H), 2.90 (t, J = 6.00 Hz, 2
H), 3.30 (t, J = 6.00 Hz, 2H), 3.90 (s, 4 H), 5.93 (bs, 2 H), 6.60
(d, J = 8.3 Hz, 1 H), 7.08–7.18 (m, 2 H), 7.49 (d, J = 8.30 Hz, 1
H), 7.65 (t, J = 7.00 Hz, 2 H), 7.72 (d, J = 7.70 Hz, 2 H), 8.48
(d, J = 4.50 Hz, 2 H). 13C-Apt (100 MHz, CDCl3): δ 12.32,
28.48 (2C), 35.02, 36.99, 40.45, 52.57, 53.40, 60.37 (2C),
108.04, 110.68, 113.43, 116.19, 122.09 (2C), 123.29 (2C),
129.28, 136.64 (2C), 141.68, 142.61, 148.80 (2C), 150.51,
156.08, 159.04 (2C), 171.04, 194.93. HRMS (ESI) calcd for
C31H36N7O2: 538.2930 [M + H]+; Found 538.2923.
Spectroscopic materials and methods. Stock solutions (0.001
M) of zinc/cadmium perchlorate were prepared in HEPES buffer
(25 mM HEPES, 0.1 M NaClO4, pH = 7.4, I = 0.1). Stock solu-
tions (0.001 M) of ZnABA′, CdABA and CdABA′ were pre-
pared in EtOH. All the fluorescence spectra of ZnABA′, CdABA
and CdABA′ were also measured in HEPES buffer [25 mM
HEPES, 0.1 M NaClO4, pH = 7.4, I = 0.1, 1% (v/v) EtOH] and
2-Bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-2-
yl)benzonitrile (8b). Compound 1 (250 mg, 1.47 mmol, 1.00
equiv.) was dissolved in DMF, and 2-bromo-4-fluorobenzonitrile
(7; 354 mg, 1.77 mmol, 1.20 equiv.) and Cs2CO3 (955 mg,
2.94 mmol, 2.00 equiv.) were added. The reaction mixture was
stirred at room temperature for 30 min and then heated in a
This journal is © The Royal Society of Chemistry 2012
Org. Biomol. Chem., 2012, 10, 6279–6286 | 6285